Australia's most trusted source of pharma news
Wednesday, 11 December 2013
Lost Your Access?
Injectables boost for Alphapharm
Alphapharm owner Mylan has completed the acquisition of injectables maker Agila and is indicating the deal could mean significant additions to its Australian portfolio.
TGA trimmed new Humira use
AbbVie's requested indication for Humira in ulcerative colitis was only partially granted by the TGA, documents newly released by the regulator show.
API doing well outside drugs
The continued roll out of Priceline Pharmacy has helped drug wholesaler API lift non-dispensing sales by over 50 per cent in the first quarter of 2013-14.
AbbVie the big immunology spender
After being born out of Abbott at the start of this year, AbbVie launched itself onto the local medical education scene by spending heavily on immunologists, a new analysis of med ed event reporting shows.
Cancer drug fund talk premature
Despite media reports last weekend talking up the prospect of an Australian cancer drugs fund similar to that in the UK, the Health Minister's office is hosing down speculation.
Pfizer opens up clinical data
Pfizer is pushing the boundaries in allowing access to clinical trial data, broadening researcher and patient access and starting an online portal.
R&D incentive bill to be reviewed
A bill around tax incentive payments for R&D spending has been referred to the Senate's economics legislation committee for an inquiry and report by 17 March next year (updated 1:24pm).
Spending on cardio med ed slumps
Medical education spending on cardiovascular HCPs has fallen 30 per cent in two years as many of the best-selling cardio drugs fall prey to generic competition, new analysis has found.
Pharma viability 'paramount': Dutton
"The viability of the medicines industry... is absolutely paramount to the future of our country," Health Minister Peter Dutton has told the House of Representatives, but he has stopped short of a commitment to use PBS savings to fund new medicines
Pfizer faces double damage claims
A patent case over Pfizer's antidepressant
is looking to run into its sixth year, with generics companies and the Commonwealth wrangling over damages after a failed IP defence
New country head for Sandoz
Generics maker Sandoz has a new coutry head for Australia with Abbott senior staffer and former Alphapharm leading light Allan Tillack joining the Novartis subsidiary last week
Oncology dominates med ed spend
A new analysis has shown that the pharmaceutical industry spent $4.4 million on oncology and haematology medical education events alone in the most recently reported six months, or 15 per cent of its total medical education spending for the half-year period
Patent war engulfs Hep C pipeline
A global patent dispute, which includes Australia, has broken out between Gilead and Idenix just as Gilead's next generation hepatitis C drug, sofosbuvir, nears FDA approval
Generics exporter plans Aust launch
Eris Pharma, which has been exporting TGA-approved medicines from Australia since 2010, will launch its first products onto the local market in January, sales director Paul Freeman has told
Pharma in Focus
Sanofi faces Apotex damages claim
Apotex's reaction to the High Court decision in the leflunomide case has been to claim a victory and say Sanofi now faces damages claims
Rival recall system won't replace TGA
The TGA has moved to "address any industry confusion" about the newly launched GS1 Recallnet Healthcare system, telling sponsors it is not compulsory
New code to require privacy consents
Medicines Australia's code review panel has agreed that under the new transparency, explicit consent to collect and publish data about payments or transfers of value must be sought from HCPs in advance
Pharmac crows over Duckett report
Steffan Crausaz, chief executive of NZ drug funder Pharmac has used the Grattan Institute's
Australia's Bad Drug Deal
report to back claims that NZ gets better value from its drug reimbursement system than Australia in terms of price
AZ, Ranbaxy settle Nexium IP dispute
AstraZeneca has confirmed that the appeal against a Federal Court decision to uphold patents on
has been dismissed "as part of a confidential settlement between the parties"
CSL pushes 2014-15 pipeline
CSL is planning five new product launches over the next two years the company told analysts at a broad overview of its global R&D portfolio and new product pipeline held in Sydney yesterday
Working Life - NEW TODAY
Selling ideas to your boss
How do you successfully pitch ideas to your pharma boss? The key lies in grasping opportunities to transform an idea into a reality - like one marketer did at MSD - writes
Blood cancer drugs at key US meeting
Data for blood cancer drugs reported to the American Society for Hematology; FDA passes Sovaldi; AZ's inhaled flu vax approved in Europe.
Bayer colorectal cancer drug passed
One of the products that Bayer boss Rene Klemm identified in March this year when it won FDA approval as key to the company's pipeline in Australia has been approved by the TGA
Nadjarian on pharma's greatest challenge
In the second part of our exclusive interview with Fred Nadjarian, the retiring Roche MD talks about pharma's greatest challenge and its biggest untold story
New laws to change customer privacy rules
New $1.7 million penalties for breaches and increased powers to name and shame offenders come in under the new privacy laws due this March.
examines the potential effects on companies that use customer data
Events & Conferences
© 2003 - 2013 Lush Media
Pharma in Focus
Jolly Good Design